Nonalcoholic fatty liver disease and hepatocellular carcinoma
-
摘要: 肝细胞癌(HCC)的病因正在悄然发生变化,欧美发达国家及部分亚洲国家非酒精性脂肪性肝病(NAFLD)相关HCC发病率逐渐增加。介绍了NAFLD与相关HCC的密切关系,NAFLD相关HCC的危险因素、临床病理特征及预防和筛查,指出NAFLD发病率尽管不如乙型肝炎和丙型肝炎相关HCC高,但因NAFLD基数大,其绝对数量不在少数,尤其是合并糖尿病和肥胖或肝纤维化/肝硬化高危患者。NAFLD相关HCC多见于老年,合并症较多,整体预后不佳。认为预防的重点在于有效治疗NAFLD,对高危人群进行严密筛查以便发现早期HCC,甲胎蛋白及CT等影像检查是主要的筛查方法,但目前尚缺乏针对NAFLD相关HCC早期预警的措施。Abstract: As the etiology of hepatocellular carcinoma( HCC) has been changing,the incidence of HCC related to nonalcoholic fatty liver disease( NAFLD) is gradually increasing in developed countries in Europe and America and some countries in Asia. This article introduces the close association between NAFLD and HCC,risk factors,clinicopathological features,and prevention and screening,and points out that although the incidence of NAFLD is not as high as that of hepatitis B- or hepatitis C- related HCC,there are a large absolute number of NAFLD patients,especially the high- risk patients with diabetes and obesity,or liver fibrosis / cirrhosis,due to a huge base number of NAFLD patients. NAFLD- related HCC is commonly seen in the elderly with various comorbidities and a poor prognosis. This article also points out that the prevention should focus on the effective treatment of NAFLD. The strict screening of high- risk population is the strategy for the diagnosis of early- stage HCC. At present,the sensitivity of alpha- fetoprotein is relatively low,and imaging examinations including computed tomography are the main screening methods; however,there are no measures for early warning of NAFLD- related HCC.
-
Key words:
- fatty liver /
- carcinoma,hepatocellular /
- metabolic syndrome X
-
[1]GOH GB,CHANG PE,TAN CK.Changing epidemiology of hepatocellular carcinoma in Asia[J].Best Pravt Res Clin Gastroenterol,2015,29(6):919-928. [2]SANYAL A,POKLEPOVIC A,MOYNEUR E,et al.Populationbased risk factors and resource utilization for HCC:US perspective[J].Curr Med Res Opin,2010,26(9):2183-2191. [3]YOUNOSSI ZM,KOENIG AB,ABDELATIF D,et al.Global epidemiology of non-alcoholic fatty liver disease-Meta-analytic assessment of prevalence,incidence and outcomes[J].Hepatology,2015.[Epub ahead of print] [4]MITTAL S,SADA YH,EL-SERAG HB,et al.Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population[J].Clin Gastroenterol Hepatol,2015,13(3):594-601. [5]WONG RJ,CHEUNG R,AHMED A.Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S[J].Hepatology,2014,59(6):2188-2195. [6]YASUI K,HASHIMOTO E,KOMORIZONO Y.Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma[J].Clin Gastroenterol Hepatol,2011,9(5):428. [7]WEINMANN A,ALT Y,KOCH S,et al.Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma[J].BMC Cancer,2015,15:210. [8]LEUNG C,YEOH SW,PATRICK D,et al.Characteristics of hepatocellular carcinoma in cirrhotic andnon-cirrhotic non-alcoholic fatty liver disease[J].World J Gastroenterol,2015,21(4):1189-1196. [9]HASHIMOTO E,YATSUJI S,TOBARI M,et al.Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis[J].J Gastroenterol,2009,44(Suppl 19):89-95. [10]WELZEL TM,GRAUBARD BI,QURAISHI S,et al.Populationattributable fractions of risk factors for hepatocellular carcinoma in the United States[J].Am J Gastroenterol,2013,8(8):1314-1321. [11]JEE SH,YUN JE,PARK EJ,et al.Body mass index and cancer risk in Korean men and women[J].Int J Cancer,2008,123(8):1892-1896. [12]NOUREDDIN M,RINELLA ME.Nonalcoholic fatty liver disease,diabetes,obesity,and hepatocellular carcinoma[J].Clin Liver Dis,2015,19(2):361-379. [13]OHKI T,TATEISHI R,SHIINA S,et al.Visceral fat accumulation is an independent risk factor for hepatocellular carcinoma recurrence after curative treatment in patients with suspected NASH[J].Gut,2009,58(6):839-844. [14]HASSAN MM,ABDEL-WAHAB R,KASEB A,et al.Obesity early in adulthood increases risk but does not affect outcomes of hepatocellular carcinoma[J].Gastroenterology,2015,149(1):119-129. [15]NAIR S,VANATTA JM,ARTEH J,et al.Effects of obesity,diabetes,and prior abdominal surgery on resource utilization in liver transplantation:a single-center study[J].Liver Transpl,2009,15(11):1519-1524. [16]DYAL HK,AGUILAR M,BARTOS G,et al.Diabetes mellitus increases risk of hepatocellular carcinoma in chronic hepatitis C viruspatients:a systematic review[J].Dig Dis Sci,2016,61(2):636-645. [17]MARGINI C,DUFOUR JF.The story of HCC in NAFLD:from epidemiology,across pathogenesis,to prevention and treatment[J].Liver Int,2016,36(3):317-324. [18]RAFF EJ,KAKATI D,BLOOMER JR,et al.Diabetes mellitus predicts occurrence of cirrhosis and hepatocellular cancer in alcoholic liver and non-alcoholic fatty liver diseases[J].J Clin Transl Hepatol,2015,3(1):9-16. [19]ADAMI HO,CHOW WH,NYRN O,et al.Excess risk of primary liver cancer in patients with diabetes mellitus[J].J Natl Cancer Inst,1996,88(20):1472-1477. [20]SINGH S,SINGH PP,SINGH AG,et al.Anti-diabetic medications and the risk of hepatocellular cancer:a systematic review and meta-analysis[J].Am J Gastroenterol,2013,108(6):881-891. [21]SORRENTINO P,D'ANGELO S,FERBO U,et al.Liver iron excess in patients with hepatocellular carcinoma developed on nonalcoholic steatohepatitis[J].J Hepatol,2009,50(2):351-357. [22]MIKURIYA Y,TASHIRO H,KOBAYASHI T,et al.Clinicopathological features of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease[J].Langenbecks Arch Surg,2015,400(4):471-476. [23]IIDA H,AIHARA T,IKUTA S,et al.Clinicopathological characteristics of hepatitis B surface antigen-negative and hepatitis C antibody-negative hepatocellular carcinoma[J].Oncol Lett,2015,10(4):2233-2238. [24]SAAB S,MALLAM D,COX GA,et al.Impact of coffee on liver diseases:a systematic review[J].Liver Int,2014,34(4):495-504. [25]BOSETTI C,FRANCHI M,NICOTRA F,et al.Insulin and other antidiabetic drugs and hepatocellular carcinoma risk:a nested case-control study based on Italian healthcare utilization databases[J].Pharmacoepidemiol Drug Saf,2015,24(7):771-778. [26]BHAT A,SEBASTIANI G,BHAT M.Systematic review:preventive and therapeutic applications of metformin in liver disease[J].World J Hepatol,2015,7(12):1652-1659. [27]AMR KS,EZZAT WM,ELHOSARY YA,et al.The potential role of miRNAs 21 and 199-a in early diagnosis of hepatocellular carcinoma[J].Gene,2016,575(1):66-70. [28]HOWELL JA,SHARMA R.The clinical role of‘liquid biopsy’in hepatocellular carcinoma[J].Hepatic Oncology,2016,3(1):45-55.
本文二维码
计量
- 文章访问数: 2508
- HTML全文浏览量: 41
- PDF下载量: 492
- 被引次数: 0